Bank of America
CMTA

Bank of America’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Bank of America’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-484
Closed -$7K – 7503
2018
Q1 		$7K Buy
+484
New +$7.88K ﹤0.01% 6717

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bank of America's CMTA Position: Q2 2018 in Review

Bank of America sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2018, closing a stake of 484 shares — an estimated $7K sold.

Bank of America first reported a position in CMTA in Q1 2018 and held it in 1 quarter. The position peaked at $7K in Q1 2018. 29 funds tracked by Wall St. Rank hold CMTA as of Q2 2018.

  • Bank of America reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Bank of America sold 484 Clementia Pharmaceuticals Inc. shares in Q2 2018, an estimated $7K.
  • Bank of America first reported a position in Clementia Pharmaceuticals Inc. in Q1 2018 and held it in 1 quarter.
  • Bank of America's Clementia Pharmaceuticals Inc. position peaked at $7K in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2018.

Based on Bank of America's 13F filing for Q2 2018, filed 14 Aug 2018.